Nonsteroidal anti inflammatory drugs NSAIDs

Description(S)-2-(2-Bromophenyl)-4-isopropyl-5,5-dimethyl-4,5-dihydrooxazole can be used as a key intermediate for the preparation of (S)-5,5-(dimethyl)-i-Pr-PHOX, a chiral ligand employed in the palladium-catalyzed asymmetric transformations.

(S)-2-AMINO-3-PIPERAZIN-1-YL-PROPIONIC ACID HCL.

(S)-3-Amino-piperidine-2-one.

(S)-3-Amino-piperidine-2-one.

(S)-3-Amino-piperidine-2-one.

(S)-3-tert-Butyl-2,5-piperazinedione.

AL 8810 is an 11&beta-fluoro analog of PGF2&alpha which acts as a potent and selective antagonist at the FP receptor. (S)-AL 8810 is the C-15 epimer of AL 8810, having the inverse, (S), or &ldquonatural&rdquo configuration at C-15 relative to AL

AL 8810 is an 11&beta-fluoro analog of PGF2&alpha which acts as a potent and selective antagonist at the FP receptor. (S)-AL 8810 is the C-15 epimer of AL 8810, having the inverse, (S), or &ldquonatural&rdquo configuration at C-15 relative to AL

AL 8810 is an 11&beta-fluoro analog of PGF2&alpha which acts as a potent and selective antagonist at the FP receptor. (S)-AL 8810 is the C-15 epimer of AL 8810, having the inverse, (S), or &ldquonatural&rdquo configuration at C-15 relative to AL

An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC₅₀s = 62 and 122

An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC₅₀s = 62 and 122

An enantiomer of ibuprofen that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form also inhibits activation of NF-&kappaB more effectively than (R)-ibuprofen (IC₅₀s = 62 and 122